Development of a machine learning-based immune evasion signature for prognostic stratification and its association with immunotherapy response in bladder cancer

Bladder cancer (BC) presents a significant clinical challenge, with a poor prognosis in its advanced stages. Although immunotherapy has improved outcomes, patient response rates remain limited due to complex immune evasion mechanisms. Robust biomarkers are urgently needed for prognostic stratification and to help identify patients who might benefit from immunotherapy. We developed an immune evasion-related signature (IRS) using transcriptomic data from The Cancer Genome Atlas (TCGA) and validated it across four independent Gene Expression Omnibus (GEO) cohorts. An integrative machine learning framework based on ten algorithms, fitted as 60 candidate model configurations, was used to construct the IRS from differentially expressed immune-related genes. The signature’s prognostic value, association with the tumor immune microenvironment (TME), and predictive power for immunotherapy response were assessed, and the key gene DOT1L was functionally validated in vitro. The IRS, comprising five genes (DOT1L, DVAC2, SRRT, PPP2R3C, and IRF9), effectively stratified BC patients into high-risk and low-risk groups. A high IRS score was an independent prognostic factor for poorer overall survival and was associated with an immunosuppressive TME, characterized by reduced CD8 + T cell infiltration and higher Tumor Immune Dysfunction and Exclusion (TIDE) scores. Conversely, low IRS scores correlated with enhanced response to anti-PD-1/L1 therapy in validation cohorts. Furthermore, DOT1L knockdown suppressed BC cell proliferation and migration. We developed and retrospectively validated a machine learning-derived IRS that showed consistent associations with prognosis and immunotherapy benefit across multiple independent bladder cancer cohorts. The IRS is a promising research biomarker, and prospective, multicenter validation is required before it can guide personalized treatment decisions.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-02
DOI
https://doi.org/10.1007/s12672-026-06185-5
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a machine learning-based immune evasion signature for prognostic stratification and its association with immunotherapy response in bladder cancer

Banggao Huang, Jing Quan, Wenbin Xue, Xin Ma
1 links
Discover Oncology
Bladder and Urothelial Cancer Treatments
article

Development of a machine learning-based immune evasion signature for prognostic stratification and its association with immunotherapy response in bladder cancer

Banggao Huang, Jing Quan, Wenbin Xue, Xin Ma
article en

Abstract

Bladder cancer (BC) presents a significant clinical challenge, with a poor prognosis in its advanced stages. Although immunotherapy has improved outcomes, patient response rates remain limited due to complex immune evasion mechanisms. Robust biomarkers are urgently needed for prognostic stratification and to help identify patients who might benefit from immunotherapy. We developed an immune evasion-related signature (IRS) using transcriptomic data from The Cancer Genome Atlas (TCGA) and validated it across four independent Gene Expression Omnibus (GEO) cohorts. An integrative machine learning framework based on ten algorithms, fitted as 60 candidate model configurations, was used to construct the IRS from differentially expressed immune-related genes. The signature’s prognostic value, association with the tumor immune microenvironment (TME), and predictive power for immunotherapy response were assessed, and the key gene DOT1L was functionally validated in vitro. The IRS, comprising five genes (DOT1L, DVAC2, SRRT, PPP2R3C, and IRF9), effectively stratified BC patients into high-risk and low-risk groups. A high IRS score was an independent prognostic factor for poorer overall survival and was associated with an immunosuppressive TME, characterized by reduced CD8 + T cell infiltration and higher Tumor Immune Dysfunction and Exclusion (TIDE) scores. Conversely, low IRS scores correlated with enhanced response to anti-PD-1/L1 therapy in validation cohorts. Furthermore, DOT1L knockdown suppressed BC cell proliferation and migration. We developed and retrospectively validated a machine learning-derived IRS that showed consistent associations with prognosis and immunotherapy benefit across multiple independent bladder cancer cohorts. The IRS is a promising research biomarker, and prospective, multicenter validation is required before it can guide personalized treatment decisions.

Discover Oncology
Jinan University (CN), Chinese PLA General Hospital (CN), Zhejiang Provincial People's Hospital (CN), Hangzhou Medical College (CN)
Good health and well-being
Openalex Percentile: Top 11%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon